SAN DIEGO--(BUSINESS WIRE)--PURE Bioscience, Inc. (NASDAQ:PURE), the creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced it has finalized a reverse stock split. As previously announced in a news release dated August 1, 2012, Pure Bioscience’s stockholders approved a reverse stock split at the Company’s annual meeting of stockholders convened July 31, 2012. The Company’s Board of Directors was authorized to proceed with an amendment to the Company’s Certificate of Incorporation to effect a reverse stock split and determine the effective date of the reverse split and the ratio of the split within a range of no less than 1-for-4 or greater than 1-for-10.
